Tao Yu

Tao Yu

Auto-generated profile, based on publicly available information

Tao Yu

Department of Biochemistry and Molecular Biology, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
TYTao Yu
Tao Yu
QZQi Zhang
Qi Zhang
SYShao-Kun Yu
Shao-Kun Yu
FNFeng-Qi Nie
Feng-Qi Nie
MZMei-Ling Zhang
Mei-Ling Zhang
KLKai-Hua Lu
Kai-Hua Lu
The THO complex (THOC) is ubiquitously involved in RNA modification and various THOC proteins have been reported to regulate tumor development. However, the role of THOC3 in lung cancer remains unknown. In this study, we identified that THOC3 was highly expressed in lung squamous cell carcinoma (LUSC) and negatively associated with prognosis. THOC3 knockdown inhibited LUSC cell growth, migration, and glycolysis. THOC3 expression was regulated by TRiC proteins, such as CCT8 and CCT6A, which supported protein folding. Furthermore, THOC3 could form a complex with YBX1 to promote PFKFB4 transcription. THOC3 was responsible for exporting PFKFB4 mRNA to the cytoplasm, while YBX1 ensured the stability of PFKFB4 mRNA by recognizing m5C sites in its 3′UTR. Downregulation of PFKFB4 suppressed the biological activities of LUSC. Collectively, these findings suggest that THOC3, folded by CCT proteins can collaborate with YBX1 to maintain PFKFB4 expression and facilitate LUSC development. Therefore, THOC3 could be considered as a novel promising therapeutic target for LUSC.

25 December 2022 in Cell & Bioscience
Verified
Journal Article
Open access
PDF file
TYTao Yu
Tao Yu
FWFuxia Wu
Fuxia Wu
YJYan Jia
Yan Jia
XZXue Zhang
Xue Zhang
XQXiaozhen Qi
Xiaozhen Qi
YLYankun Liu
Yankun Liu
Background: N6-methyladenosine is the most abundant eukaryotic mRNA modification and alters a wide range of cellular processes in cancer. Therefore, defining the molecular details are critical for understanding the regulatory mechanism of m6A modification. Results: We found that METTL3, a core m6A methyltransferase component, is upregulated and functions as an oncogene in cervical cancer. Mechanistically, METTL3 induces the degradation of m6A-modified transcripts of NR4A1 though YTHDF2-DDX6 pathway. In addition, NR4A1 overexpression attenuates the malignant progression through recruiting the LSD1/HDAC1/CoREST transcriptional repression complex to AKT1 promoter. Conclusions: Our findings reveal that m6A regulates cervical cancer cellular progression through manipulating NR4A1 pathway.

1 November 2024 in Science Advances
Verified
Journal Article
Open access
YYYingyun Yang
Yingyun Yang
DWDahan Wen
Dahan Wen
FLFeng Lin
Feng Lin
XSXiaowei Song
Xiaowei Song
RPRuiyang Pang
Ruiyang Pang
YLYuying Liu
Yuying Liu
Increasing evidence highlights the importance of immune mechanoregulation in establishing and sustaining tumor-specific cytotoxicity required for desirable immunotherapeutic outcomes. However, the molecular connections between mechanobiological inputs and outputs and the designated immune activities remain largely unclear. Here, we show that partial inhibition of non-muscle myosin II (NM II) augmented the traction force exerted by T cells and potentiated T cell cytotoxicity against tumors. By using T cells from mice and patients with cancer, we found that NM II is required for the activity of NKX3-2 in maintaining the expression of ADGRB3, which shapes the filamentous actin (F-actin) organization and ultimately attributes to the reduced traction force of T cells in the tumor microenvironment. In animal models, suppressing the NM II–NKX3-2–ADGRB3 pathway in T cells effectively suppressed tumor growth and improved the efficacy of the checkpoint-specific immunotherapy. Overall, this work provides insights into the biomechanical regulation of T cell cytotoxicity that can be exploited to optimize clinical immunotherapies.

15 February 2022 in Epileptic Disorders
Verified
Journal Article
Closed access
PDF file
GHGuiliang Hao
Guiliang Hao
XWXueyuan Wang
Xueyuan Wang
HYHao Yan
Hao Yan
LHLiu He
Liu He
DNDuanyu Ni
Duanyu Ni
TYTao Yu
Tao Yu
Limb loss experience is a type of body illusion characterized by the sensation of a missing limb or body part. We aimed to investigate the brain areas involved in this unusual somatosensory experience evoked by electric cortical stimulation with stereo-electroencephalography electrodes. We retrospectively reviewed the data of patients with medical intractable epilepsy, from October 2015 to December 2020, who underwent stereo-electroencephalography implantation and electric cortical stimulation in order to locate the epileptogenic zone and obtain a functional map. We included patients who reported experiences of limb loss during the process of electric cortical stimulation for functional mapping. Three patients reported experiences of limb loss in the process of electric cortical stimulation. Limb loss experience (including the right hand, right upper limb and right side of the body) occurred when the cortex of the left posterior insula, posterior dorsal cingulate and parietal operculum were stimulated. Limb loss experience can be evoked by electric cortical stimulation of the posterior insula, parietal operculum, and posterior cingulate cortex, and provides additional evidence that these cortices play a role in the integration of body sensory perception.

3 April 2023
Verified
Other
Open access
Richard L BennettRichard L Bennett
Richard L Bennett
ABAditya Bele
Aditya Bele
ESEliza C. Small
Eliza C. Small
CWChristine M. Will
Christine M. Will
BNBehnam Nabet
Behnam Nabet
JLJonathan D. D Licht
Jonathan D. D Licht
List of all H4 missense mutations in cBioPortal nad dbSNP analysis

28 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
TYTao Yu
Tao Yu
MJMeng Ji
Meng Ji
DYDonglin Yu
Donglin Yu
ZGZhao Guan
Zhao Guan
RZRongyi Zhu
Rongyi Zhu
KLKailong Li
Kailong Li
CRISPR-based epigenome editing represents a programmable strategy to precisely modulate gene expression, holding immense promise for therapeutic applications. However, the large size of the dCas proteins substantially impedes the delivery via adeno-associated virus (AAV) vectors. Here, through iterative bioinformatics analysis, structure-guided predictions, and functional assays, we identified and characterized PmCas12m, a novel miniature subtype V-M CRISPR-Cas12m. PmCas12m exhibited flexible 5’-YTN-3’ PAM-dependent recognition and robust double-stranded DNA binding properties, while lacking DNA cleavage activity, thus positioning it as an ideal tool for epigenome editing. Cryogenic electron microscopy (cryo-EM) structures of PmCas12m unveiled its unique molecular mechanism of DNA binding facilitating interference. Guided by these structural insights, we employed deep mutational scanning (DMS) and protein engineering to develop xCas12m, a hypercompact variant with highly potent and specific epigenome editing capabilities in human cells. We further constructed the xCas12m-CRISPRoff platform in a single AAV vector, which achieved durable epigenetic silencing and effective inhibition of hepatitis B virus (HBV) infection in a mouse model. Collectively, these findings establish xCas12m as a versatile epigenome editing platform with transformative potential for treating diseases, paving the way for clinical translation of epigenetic therapies.